Fungal diseases in burn and blast-injured patients: tensions are rising, and awareness must keep pace

Invasive fungal diseases (IFD) are severe complications of burn injury and are associated with substantial morbidity and mortality. Despite increasing recognition of their clinical impact, evidence guiding diagnosis, prevention, and management remains limited. This review summarizes recent advances in the understanding of host susceptibility, diagnostic approaches, and therapeutic strategies for IFD in burn patients.

Recent literature converges on three major themes: the characterization of burn-induced immunosuppression, the need to associate conventional diagnostics and molecular tools, including quantitative PCR and the central role of comprehensive source control, to which systemic antifungal therapy must be systematically added and pharmacokinetically optimized to account for the profound physiological alterations inherent to severe burn injury.

Optimal management of IFD in burn patients requires a multidisciplinary approach combining immune risk stratification, refined diagnostic algorithms, and individualized antifungal therapy. Consensus on case definitions and prospective multicentre data are urgently needed to consolidate the evidence base and meaningfully improve outcomes in this vulnerable population.